ARTICLE | Clinical News

AnaptysBio's ANB020 meets objective in Phase IIa for atopic dermatitis

October 13, 2017 7:47 PM UTC

AnaptysBio Inc. (NASDAQ:ANAB) said lead program ANB020, an antibody against IL-33, “achieved the trial protocol objective” in a Phase IIa trial to treat moderate to severe atopic dermatitis. The company said the trial had no prespecified primary endpoint.

The trial's key efficacy objective evaluated whether a single dose of IV ANB020 could lead to a 50% improvement in Eczema Area and Severity Index score (EASI 50) in ≥50% of patients at week 4. Among the trial's 12 patients, 83% achieved an EASI 50 response at day 29 and 75% achieved an EASI 50 response at day 57. Additionally, ANB020 led to an EASI 75 response in 33% of patients at day 29 and 42% of patients at day 57. Compared to baseline, ANB020 led to reductions in mean EASI and pruritus scores of 61% and 32%, respectively, at day 29 and of 62% and 21%, respectively, at day 57. ANB020 was generally well tolerated with no serious adverse events reported...

BCIQ Company Profiles

AnaptysBio Inc.